BSE: 536565
NOVELIX PHARMACEUTICALS LIMITE
The company operates a pharmaceutical business that generated Rs. 25.1936 crore from its named Pharma Business segment in FY26, up from Rs. 20.861 crore in FY25, against total FY26 revenue of Rs. 132.3062 crore. In June 2026, it signed an agreement with GMBU e.V., a research organisation in Halle (Saale), Germany, to scale up commercial production of Astaxanthin, a natural antioxidant pigment used in nutraceuticals and aquaculture, at its research facilities in Hyderabad, after successful pilot-scale work. The company is funding this expansion through preferential share issues: 12 lakh shares were allotted to 18 non-promoter investors at Rs. 57 each, raising Rs. 6.84 crore, alongside 33.75 lakh warrants converted by promoter-group entities at Rs. 20 each, raising Rs. 5.06 crore. The non-promoter issue proceeds are earmarked for technology transfer from GMBU Germany, a land lease deposit at Siddipet, land development, consumables, pre-operative expenses, and quality control equipment, with deployment targeted before September 30, 2026. EBIT from the Pharma Business in FY26 was Rs. 1.2329 crore, with total net profit of Rs. 2.5566 crore and an EBITDA margin of 2.6495%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharma Business, Other operations. Small-cap pharmaceutical and biotech research company at a capital-raising stage
Exhibit 1: Financial summary, FY19–FY21 (all audited; no estimate years)
| ₹ crore · consolidated | FY19 | FY20 | FY21 |
|---|---|---|---|
| Revenue | 10 | 10 | 9 |
| EBITDA (ex other income) | (0) | (1) | (4) |
| margin % | (1.5) | (5.0) | (41.1) |
| Owners' profit | 0 | 0 | (4) |
| EPS, as reported (₹) | (0.03) | (0.35) | (4.62) |
| ROE % · ROCE % | (1.3) · 0.0 | (2.3) · (0.8) | (51.1) · (49.5) |
| Debt / equity (x) | 0.08 | 0.07 | 0.00 |
| Cash from operations | — | — | 2 |
| Capex | — | — | (0) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY21 | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q1 FY23 | Q2 FY23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 4 | 2 | 1 | 1 | 1 |
| Profit before tax | (0) | (0) | (3) | (0) | 0 | (1) | (0) | (0) |
| Net profit | (0) | (0) | (3) | (0) | 0 | (1) | (0) | (0) |
| EPS (₹) | (0.21) | (0.26) | (4.05) | (0.18) | 0.39 | (0.77) | (0.11) | (0.19) |
Exhibit 3: Segment revenue, FY21
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharma Business | 5 | 47.0 |
| Financial Services | 0 | 3.5 |
| Investments | 0 | 0.1 |
| Foods | 4 | 39.1 |
| Trading in Shares | 1 | 10.3 |
| Total, before eliminations | 10 | 100.0 |
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| Jeevan Scientific Technology L | 163 | 195.0 | 2.24 | 15.8 | 1.4 | 2.4 | 5.1 | 21.5 |
| NOVELIX PHARMACEUTICALS LIMITE ◆ | 146 | — | 19.66 | — | (3.3) | (3.3) | — | (9.5) |
| GlobalSpace Technologies Limit | 82 | 26.9 | 1.44 | 18.1 | 5.0 | 3.4 | 13.7 | 7.1 |
| Adeshwar Meditex Limited | 23 | 21.1 | — | — | — | — | — | — |
| Vanta Bioscience Limited | 15 | 3.3 | — | — | — | 0.0 | (29.0) | — |
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 19.7 | 4.6 | 57 of 57 | 0% |
| ROCE | (3.3) | 8.0 | 61 of 69 | 12% |
| ROE | (3.3) | 9.1 | 52 of 57 | 9% |
| Debt / Equity | 0.0 | 0.1 | 18 of 56 | 69% |
| EBITDA margin | (9.5) | 21.5 | 54 of 57 | 5% |
| Revenue growth | (71.5) | 20.2 | 55 of 57 | 4% |
| Profit growth | (105.5) | 11.4 | 48 of 55 | 13% |
| Market cap | 146 | 229 | 43 of 71 | 40% |
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 6 Oct 2026 · RTA compliance certificate for Q2 FY27 dematerialisation filed | compliance | minimal | — | — |
| 2 Oct 2026 · Novelix Pharmaceuticals: New Whole Time Director Appointed | board shareholder meetings | low | — | — |
| 1 Oct 2026 · 32nd AGM: All 3 resolutions passed with 99.97 percent majority | board shareholder meetings | low | — | — |
| 1 Oct 2026 · 32nd AGM results: all 3 resolutions passed with 99.97% majority | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Novelix Pharma 32nd AGM outcome: 3 resolutions passed via e-voting | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Trading window closed ahead of Q2 financial results | compliance | minimal | — | — |
| 9 Sept 2026 · Newspaper publication of 32nd AGM notice and e-voting info submitted to BSE | compliance | minimal | — | — |
| 7 Sept 2026 · AGM Notice and Annual Report Web Link Shared with Shareholders | management changes | low | — | — |
| 7 Sept 2026 · Novelix Pharmaceuticals 32nd AGM notice on Sept 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Submission of annual report and 32nd AGM notice for FY 2025-26 | board shareholder meetings | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.